Kornimate/medical-research-clean huggingface dataset:
changes in patient reported constipation among advanced cancer patients after receiving an educational intervention

Conditions: Advanced Cancers

Summary: the goal of this research study is to learn how patients' think about constipation before and after receiving education about the subject.

if participant agrees to take part in the study, information about them (such as their age, gender, ethnicity, religion, diagnosis, and drugs they are currently taking) will be collected from their medical record. participant will also complete 1 questionnaire about constipation. it should take about 1-3 minutes to complete the questionnaire. after completing the questionnaire, participant will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. this is done because no one knows if one study group is better, the same, or worse than the other group. participant will have an equal chance of being in either group. * if participant is assigned to group 1, they will watch a short educational video. * if participant is assigned to group 2, they will read a fact sheet. both the video and the fact sheet describe symptoms of constipation and the importance of regular bowel movements. they should take about 3 minutes each to complete. after participant has viewed the educational material, they will complete 3 questionnaires about constipation and how helpful they think the video or fact sheet was in educating them about constipation. it should take about 10 minutes total to complete these questionnaires. participant will watch the video/read the fact sheet and complete the questionnaires in their room at the supportive care clinic. length of study: patient's participation on this study will be over after they have completed the last 3 questionnaires. this is an investigational study. up to 200 participants will be enrolled in the study. all will take part at md anderson.

Eligibility criteria:
inclusion criteria: 1. patients with diagnosis of advanced cancer, including recurrent, locally advanced, or metastatic cancer 2. age \>/= 18 years old 3. patients must be able to understand, read, write, and speak english 4. patients must have no clinical evidence of cognitive impairment as determined by the palliative care physician (memorial delirium assessment score \>/= 7) 5. patients must sign an informed consent exclusion criteria: 1. patients with a diagnosis of inflammatory bowel disease, i.e. crohn's disease or ulcerative colitis 2. patients with complete or partial bowel obstruction as determined by the palliative care physician 3. patients with a bowel ostomy

Keywords: advanced cancers constipation recurrent cancer locally advanced cancer metastatic cancer video fact sheet questionnaires surveys
understanding the effects of water-related appetite expectancies on caloric intake in college students

Conditions: Appetitive Behavior; Weight Loss; Water; Energy Intake

Summary: consuming large volumes of water has recently been identified as a common weight loss strategy among u.s. adults. it is a widespread belief that drinking water increases feelings of satiety and reduces food intake, which could contribute to long-term weight maintenance. many studies have shown support for this, demonstrating water's ability to reduce hunger and energy intake. in some cases, increased water consumption was associated with weight loss. however, the mechanisms of how water affects food intake have been minimally explored. there is potential that the effect of water on reduced food intake and increased satiety is due to individuals' belief that water will reduce their appetite and food intake. the question remains if water expectancy has a meaningful influence on water's ability to reduce food intake. the investigators hypothesize that participants will report less hunger and consume fewer calories when given water and an expectancy that water will affect appetite, compared to a condition when given water and do not expect water to have an effect on appetite. we further hypothesize that calorie intake will not meaningfully differ when participants are given water with no expectancies compared to when given no water. during this experiment, the investigators will vary the presence of water and manipulate expectancies about water's effects on appetite across three conditions: (1) an expectancy and water condition; (2) an expectancy and no water condition; and (3) a no expectancy and water condition. in each condition, participants will engage in a bogus taste test and complete two short cognitive tasks for distraction purposes. in an effort to prevent demand characteristics, this study involves deception. participants will be told that the research team is interested in testing the effects of three different mint herb variations on attention, coordination, and taste perceptions. after completing the cognitive tasks and taste test, participants will have a 10 minute period to eat as much of the remaining food as they'd like. food will be weighed before and after this period (without the participant's knowledge) in order to determine caloric intake.


Eligibility criteria:
inclusion criteria: * 18 - 65 years of age * rating at least two foods from each category (chips/crackers and sweets/candies) on the food options list for the taste test as a 7 ("like moderately") or higher on a 9-point hedonic scale * willing/able to come to the lab for three sessions exclusion criteria: * current smoker * self-report of a current or past eating disorder diagnosis * taking an appetite suppressant or stimulant medication * currently engaged in a weight loss program * currently pregnant, breastfeeding, or planning to become pregnant * allergy to mint
bortezomib (velcade) in waldenstrom's macroglobulinemia

Conditions: Waldenstrom's Macroglobulinemia; Lymphoplasmacytic Lymphoma

Summary: the purpose of this study is to evaluate how tumors in patients with waldenstrom's macroglobulinemia respond to treatment with bortezomib (velcade) and to see what effects (good and bad) it has on the cancer.

* patients will receive bortezomib intravenously twice weekly for 2 weeks on days 1,4,8 and 11 of each cycle. a 10-day rest period (days 12-21) will follow the 2 weeks of treatment. the treatment cycle is repeated up to eight times depending upon the disease response and if the patient is tolerating the drugs. * the following procedures will be conducted as part of the treatment monitoring: day 1 visit (of each treatment cycle): evaluation of disease-related symptoms, vital signs and weight and blood tests. day 4 visit (of each treatment cycle): vital signs and blood work. day 8 visit (of each treatment cycle): vital signs and blood work. day 11 visit(of each treatment cycle): vital signs, blood work, and possible ct scan. * treatment will be discontinued if any of the following occur: disease gets worse, severe side-effects or the patient requires other anti-cancer therapy. * at the end of the treatment (30 days after the last dose of study drug) the patient will have a physical exam, vital signs, evaluation of disease-related symptoms, blood work and ct scan for tumor measurements. * long term follow-up consists of every 3 month clinical visits until disease progression or up to 2 years.

Eligibility criteria:
inclusion criteria: * clinicopathological diagnosis of waldenstrom's macroglobulinemia who have failed one first line therapy * measurable disease, defined as presence of immunoglobulin m (ig m) paraprotein with a minimum igm level of \>2 times uln * karnofsky performance status of \>60 * life expectancy of \> 3 months * baseline platelet count \>50,000,000,000/l and anc of 750,000,000/l * ast and alt \< 3 x uln * total bilirubin \< 2 x uln * calculated or measured creatinine clearance \> 30ml/minute * serum sodium \> 130 mmol/l exclusion criteria: * greater than or equal to grade 2 peripheral neuropathy * hypersensitivity to bortezomib, boron or mannitol * prior therapy with velcade * pregnant or lactating women

Keywords: bortezomib velcade waldenstrom's macroglobulinemia
pegvisomant and sandostatin lar combination study

Conditions: Acromegaly

Summary: the purpose of this study is to compare the safety and tolerability of combination therapy with sandostatin lar plus pegvisomant to that of sandostatin lar alone or pegvisomant alone.


Eligibility criteria:
inclusion criteria: * diagnosis of acromegaly * received previous radiation and/or surgical treatment for their gh (growth hormone) producing pituitary adenoma and have required medical therapy due to failure to normalize gh (growth hormone) and/or igf-i as a result of their primary treatment * patients that been receiving sandostatin lar for a minimum of 6 months prior to enrollment exclusion criteria: * presence of other conditions that may result in abnormal gh (growth hormone) and/or igf-i concentrations * patients on current medical therapy other than sandostatin lar * ast/alt \>= 3xuln (upper limits of normal) * pituitary adenoma within 3mm of optic chiasm confirmed by recent mri * visual field defects (except post-surgical stable residual defects) * unable to self administer drug * radiotherapy within 12 months of entering the study
association between eeg changes and hormonal response to tracheal intubation and surgical stimulation

Conditions: Abdominal Surgery; Endotracheal Intubation; Surgical Incision; Electroencephalogram

Summary: this study aims to prospectively evaluate the relationship between changes in eeg and hormonal responses induced by endotracheal intubation and surgical incision following general anesthesia.

this study aims to investigate the relationship between changes in eeg patterns and stress hormone levels in patients undergoing open abdominal surgery under general anesthesia when subjected to endotracheal intubation and surgical incision stimuli. hormone measurements (cortisol, acth) are taken at four time points: before endotracheal intubation (t1), one minute after intubation (t2), and one minute after surgical incision (t3). the investigators evaluate the correlation between hormone levels (cortisol, acth) and eeg band power changes (alpha, beta, delta) before and after endotracheal intubation and surgical incision.

Eligibility criteria:
inclusion criteria: * 1) patients scheduled to undergo open abdominal surgery under general anesthesia with endotracheal intubation. * 2) patients requiring invasive blood pressure monitoring during surgery exclusion criteria: * 1) patients transferred to the intensive care unit after surgery * 2) surgery duration of less than one hour * 3) patients with neurological underlying conditions * 4) patients on chronic use of psychotropic medications and opioid drugs * 5) emergency surgery
post-licensure department of defense (dod) screening accuracy study in military personnel

Conditions: Smallpox

Summary: this is a retrospective study of the department of defense (dod) smallpox screening form 600s (sf600s) generated during screening of service members for possible immunization with the acam2000® smallpox vaccine. primary objective: * to evaluate the accuracy of the dod smallpox vaccination screening process in military personnel. secondary objective: * to describe the number of subjects who are excluded from vaccination, stratified by the pre-defined categories for exclusion (separately for the screened and evaluable populations).

please note that we elected to post this study on the registry (clinicaltrials.gov) in the interests of transparency and because the study represented a post-licensure commitment to fda for acam2000® smallpox vaccine. however, this study was not a clinical trial and did not involve the administration of any vaccine product nor the collection of any product performance or adverse event data. rather, the purpose of the study was to determine the success rate for proper completion and use of department of defense (dod) screening form 600s (sf600s). the sf600 is a form required to be completed prior to smallpox vaccination of dod staff and is used to guide decision-making by dod vaccination staff regarding offering, postponing, or denying vaccination. the study evaluated both the extent to which the sf600s were completed correctly and the extent to which they were correctly used to guide vaccination decision-making.

Eligibility criteria:
inclusion criteria: * military personnel ≥17 years of age. * completion of the dod smallpox screening form 600 (2-part format). exclusion criteria: * none

Keywords: smallpox acam2000® smallpox vaccine
fluid responsiveness prediction using extra systoles

Conditions: Coronary Artery Bypass Graft

Summary: in this study, the investigators propose to investigate a novel technique for fluid responsiveness prediction. it is based on the occurrence of an extra systole, which induces a preload variation: extra systoles are comprised by, first, the premature/ectopic beat with decreased cardiac preload, then, the post-ectopic beat with moderately increased preload. consequently, the post ectopic beat is associated with a frank-starling curve right shift but is otherwise a normal sinus beat. as such, the post-ectopic beat elucidates and predicts the hemodynamic effect of increasing preload, i.e. giving fluids


Eligibility criteria:
inclusion criteria: * patients requiring elective cabg or opcab surgery * patient's age ≥ 18 years exclusion criteria: * patient refusal * pregnancy * ef \< 35% * end stage kidney failure (defined by the need for haemodialysis) * patients with atrial fibrillation or frequent and coupled extra systoles (e.g. trigemini)
pegylated interferon-alpha-2a in patients with malignant melanoma stage iia-iiib

Conditions: Melanoma

Summary: the purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a (peg-ifn) vs. 'low dose' interferon-α-2a in patients with malignant melanoma in stage iia (t3a) - iiib. a total of 880 will be randomized up to three months after first surgical management of their melanoma to either: peg-ifn-α-2a or low-dose interferon-α-2a.


Eligibility criteria:
inclusion criteria: * histologically proven cutaneous melanoma * ≥ 18 years of age and \< 75 years of age * have confirmed stage iia (t3a), iib, iic, iiia or iiib (ajcc 2002) melanoma (lymph node staging either per sentinel node biopsy or elective lymph node dissection) * have a karnofsky performance status of ≥ 80% * negative pregnancy test * start of therapy within three months after surgery * informed consent exclusion criteria: * pregnant or lactating women * unwillingness or inability to employ an effective barrier method of birth control throughout the study and for up to 3 months after end of treatment in female or male patients * mucous membrane or ocular melanoma * any evidence of distant metastasis (ct-scan of brain, chest x ray or ct, abdominal ultrasound or ct and ultrasound of regional lymph nodes at screening) * patients who have received chemotherapy or vaccines for melanoma * patients with tumor progression under a previous adjuvant interferon therapy or within three months after termination of interferon therapy (patients previously receiving adjuvant interferon therapy in another tumor stage without disease progression may be included) * history of any other malignancy within the last ten years (except basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix) * patients with severe cardiac disease (e.g. nyha functional class iii or iv, myocardial infarction within 6 months, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina), severe liver disease or severe renal disease. * alat or asat \> 2 x uln * bilirubin \> 2 x uln * creatinine \> 2 x uln * patients who have a history of depression or other psychiatric diseases requiring hospitalisation * patients with seizure disorders requiring anticonvulsant therapy * any of the following abnormal baseline hematologic/laboratory values: * hb \<10g/dl * wbc \<3.0 x 109 /l * platelets \<100x109/l * neutrophils \< 1.5 x 109/l * history or presence of autoimmune disease (i.e. autoimmune hepatitis, thyroid auto-immune dysfunction, systemic lupus erythematodes) * unwilling or unable to comply with the requirements of the protocol for the duration of the study * known infection with hbv, hcv, hiv * evidence of allergy or hypersensitivity against ifn or pegylated interferon * thyroid disease poorly controlled on prescribed medications * systemic corticosteroid therapy for any reason (\>1 month)

Keywords: malignant melanoma adjuvant therapy adjuvants, immunologic
comparison between diode laser and bleomycin in treatment of hemangioma

Conditions: Bleomycin Adverse Reaction

Summary: assessment of the effectiveness of bleomycin intralesional injection and diode laser on management of infantile hemangioma., with regard to : * clinically based on change in the size and color of hemangioma. * ultrasonography considering vascularity ,echogenicity , height , and morphology . * comparison of complications associated with bleomycin and diode laser.


Eligibility criteria:
inclusion criteria: * age between 3 months and 1 year old. * non complicated infantile hemangioma exclusion criteria: * younger than 3 months or older than 1 year. * complicated infantile hemangioma
current situation of natural history, diagnosis and treatment in inpatients with embolism stroke of unknown cause (esus)

Conditions: Embolic Stroke of Undetermined Source

Summary: evaluate the epidemiological characteristics, risk factors, clinical characteristics in patients with esus and their medication compliance and relapse within 1 year.

the purpose of this study is to evaluate the epidemiological characteristics, risk factors (such as hypertension, diabetes, hyperlipidemia, coronary heart disease, history of previous stroke, smoking, and alcohol consumption), clinical characteristics in patients with esus and their medication compliance and relapse within 1 year.

Eligibility criteria:
inclusion criteria: - patients diagnosed with acute cerebral infarction and treated in peking university third hospital neurology department from january 2010 to june 2016. exclusion criteria: * lacunar infarction * aortic atherosclerotic cerebral infarction * clear cardiogenic cerebral infarction * other related system diseases (arteritis, vascular dissection, migraine and vasospasm, etc.)
implementing intellicare in collaborative care: a quality improvement evaluation

Conditions: Depression

Summary: the overarching aim of the proposed project is to conduct a pragmatic, quality improvement evaluation of the intellicare platform for improving processes of care in the rush collaborative care program, and improving patient population depression outcomes, to determine the long-term utility of intellicare for rush.

this study is a pragmatic, system-wide rollout quality improvement evaluation design displayed in figure 1. the rush irb has waived consent for this quality improvement trial. data from the ehr will be used beginning december 1, 2019. the first care manager (cm) will begin enrolling patients into intellicare in september, 2020. additional cms will begin using intellicare at approximately 3 month intervals. in september 2021, support for intellicare from the evaluation team will be withdrawn, to examine the sustainability of the intellicare platform. patients data from all patients, aged 18 or older, enrolled collaborative care from december 1, 2019 through august 31, 2022 will be used to evaluate the intellicare service. all cct patients who are 18 or older, and have a smartphone will be offered enrollment.

Eligibility criteria:
inclusion criteria: * enrolled in rush collaborative care service * owns a personal smartphone exclusion criteria: * none
vitamin b12 acceptance and biomarker response study

Conditions: Vitamin B 12 Deficiency

Summary: in this study, biomarker response after supplementation with oral and intramuscular vitamin b12 will be compared in a randomized clinical trial. electronic compliance monitoring will be used to control for non compliance as a possible confounder in oral treatment. additionally subjective acceptance in terms of presumed preferences will be compared with oral vs. intramuscular supplementation of vitamin b12 in the view of the patient.


Eligibility criteria:
inclusion criteria: * general practitioner's prescription for vitamin b12 deficiency testing * age\> 18 years * ability to give written informed consent * vitamin b12 serum concentrations \< 200pmol/l * indication for vitamin b12 supplementation according to the general practitioners estimation exclusion criteria: * patients with incorrect intake of vitamin preparations containing vitamin b12 * patients with previously diagnosed dementia * patients with known hereditary transcobalamin transportation defects * lack of written and/or oral understanding in german, french, italian or english languages
evaluate cytotoxicity, leaching, and structural conformation of clear aligners

Conditions: Malocclusion; Cytotoxicity

Summary: the aim is to evaluate clear aligners' cytotoxicity, leaching, and structural properties and compare them with four cleaning tools. the null hypothesis is the cleansers have no impact on the properties tested.

orthodontic invisalign clear aligners patients will be randomly distributed into four groups using four cleaning methods. participants will be instructed to clean their trays as instructed by the production company. leaching, cytotoxicity, and structural confirmation will be evaluated of the invisalign clear aligners after being used.

Eligibility criteria:
inclusion criteria: * participants who are on invisalign clear aligner treatment. * participants who are 21 years and older and committed to their treatment. * participants with caries-free dentition * participants with no smoking habits * participants are not pregnant females exclusion criteria: * participants who are on orthognathic treatment. * participants with hypodontia.

Keywords: cytotoxicity leaching clear aligner orthodontics
erectile dysfunction and diabetes mellitus

Conditions: Diabetes Mellitus; Erectile Dysfunction

Summary: this study consists of filling out a questionnaire on possible erectile dysfunction.

male diabetic patients who attend a diabetic routine year program visit will be asked to give their voluntary permission to fill out a questionnaire on possible erectile dysfunction. the questionnaire consists of two parts: part 1 is the iief (international index of erectile function) questionnaire and part 2 is an additional questionnaire. the included patients have to fill out these questionnaires two times; once at the beginning at a diabetic year program visit and a second time one year later at the next diabetic year program consultation. the patients will also be asked to give their permission for using their results of the routine diabetic year program for scientific research.

Eligibility criteria:
inclusion criteria: * male diabetic patients * age older than 18 years exclusion criteria: